Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

Lundbeck says Alzheimer's drug fails in late-stage study, HEALTH NEWS | Thu Sep 22, 2016, Ankur Banerjee

Excerpts:
"Danish drugmaker H Lundbeck A/S's highly anticipated experimental Alzheimer's drug failed in a late-stage study, underscoring the challenges faced by drugmakers to tackle the debilitating memory-robbing disease.

The Copenhagen-based company said on Thursday both doses of the drug, idalopirdine, showed a "weak efficacy profile" and failed to reduce cognitive decline measured on a scale called ADAS-cog in the study named Starshine.

Idalopirdine, which is being developed with Japan's Otsuka Pharmaceutical Co Ltd, is being tested in patients with mild to moderate Alzheimer's disease."

"Long-awaited late-stage results from Eli Lilly and Co's experimental drug solanezumab, which is being tested in patients with mild Alzheimer's, is expected to be announced in the fourth quarter."

Article at:
http://www.reuters.com/article/us-h-lundbeck-study-idUSKCN11S2B6?feedType=nl&feedName=healthNews&utm_source=Sailthru&utm_medium=email&utm_campaign=US%20Health%20Report%202016-09-23&utm_term=US%20Health%20Report